launch

New Era; New Launch Excellence Blueprint for 2021-2022

New Era; New Launch Excellence Blueprint for 2021-2022

John Constantine, Senior VP at Orchestrall, Inc: How to Accelerate Drug and Device Launch in the Post-COVID World

New Era; New Launch Excellence Blueprint for 2021-2022
ACTO launches LAICA, the first AI-powered conversational assistant for Life Sciences learning

Episode 2: How to Accelerate Drug and Device Launch in the Post-COVID World

ACTO Named One of the 2019 PM360 ELITE 100

Four Fundamentals for Telling Your Clinical Evidence Story

Channel Partners: Gaining Visibility and Creating Accountability

ACTO Acquires Scrimmage, Disrupting Life Sciences Learning and Engagement Market

Exclusive ACTO Omnichannel Platform Mini Demo

ACTO Emerges as a Leader in Life Sciences Commercialization; Closes Strong Calendar Year 2018 with 184% Revenue Growth and Doubled Customer Base

ACTO Acquires Scrimmage

Omnichannel Education For The Life Sciences

ACTO Achieves 158% Year to Date Revenue Growth in 2019 and Has Digitally Transformed Over 50 Life Sciences Companies

Critical Insights from Industry Leaders for Successful Implementation of Commercial Digital Transformation
ACTO Appoints Jenny Yeung as Chief Financial Officer

When the Rubber Meets the Road, Don’t Slip

Channel Partners: Accessibility is the Magic Word

Episode 3: The New Model for Crisis Leadership in Life Sciences

The Triple A Initiative: ACTO, Axiom, and AstraZeneca
